These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 29038850)

  • 21. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer.
    Kudo T; Takemasa I; Hata T; Sakai D; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Satoh T; Mizushima T; Mori M; Doki Y
    Oncology; 2019; 97(4):211-216. PubMed ID: 31266024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
    Kadowaki S; Masuishi T; Ura T; Sugiyama K; Mitani S; Narita Y; Taniguchi H; Muro K
    Int J Clin Oncol; 2021 Apr; 26(4):701-707. PubMed ID: 33386556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
    Hoff PM; Saad ED; Pazdur R; Wolff R; Lassere Y; Bogaard KR; Abbruzzese JL
    Invest New Drugs; 2004 Aug; 22(3):307-13. PubMed ID: 15122078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
    Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U
    Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.
    Maroun J; Marginean H; Jonker D; Cripps C; Goel R; Asmis T; Goodwin R; Chiritescu G
    Clin Colorectal Cancer; 2018 Jun; 17(2):e257-e268. PubMed ID: 29330005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
    Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
    Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
    Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A
    Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
    Fornaro L; Masi G; Bursi S; Loupakis F; Vasile E; Antonuzzo A; Chiara S; Pfanner E; Di Paolo A; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):965-9. PubMed ID: 18839174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.
    Hecht JR; Reid TR; Garrett CR; Beck JT; Davidson SJ; Mackenzie MJ; Brandt U; Rizvi S; Sharma S
    Anticancer Res; 2015 Mar; 35(3):1567-73. PubMed ID: 25750312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
    Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
    J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
    von Moos R; Roth A; Ruhstaller T; Widmer L; Uhlmann C; Cathomas R; Köberle D; Simcock M; Lanz D; Popescu R
    Onkologie; 2010; 33(6):295-9. PubMed ID: 20523092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
    Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Giessen C; Moosmann N; Heinemann V
    Br J Cancer; 2011 Jul; 105(2):206-11. PubMed ID: 21750558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.